Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Doreen Chung

Urogynecology and Reconstructive Pelvic Surgery New Hyde Park, NY Medical Doctor

NPI 1215188214 CMS profile 9138

450 Lakeville Rd Ste M41, New Hyde Park, NY 11042

Open in the dashboard

General payments

$13,555

210 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$182,429 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Doreen Chung of New Hyde Park, NY is reported in the CMS Open Payments database as having received $13,555 across 210 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $182,429 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 68th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,892 15
2024 General $1,756 35
2023 General $4,179 49
2022 General $1,473 41
2021 General $636 17
2020 General $549 11
2019 General $2,072 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Doreen Chung
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Doreen Chung were reported at $2,892. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.

Show as a table
Year Doreen Chung Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $2,072 $799 $319–$2,013 $163
2020 $549 $384 $158–$1,360 $114
2021 $636 $641 $247–$2,515 $132
2022 $1,473 $843 $347–$2,794 $149
2023 $4,179 $819 $308–$2,302 $160
2024 $1,756 $882 $306–$2,459 $164
2025 $2,892 $779 $301–$2,705 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Axonics Modulation Technologies, Inc. $2,961 20 payments
  2. Boston Scientific Corporation $2,927 18 payments
  3. AbbVie, Inc. $1,076 15 payments
  4. Medtronic, Inc. $991 14 payments
  5. Coloplast Corp $897 17 payments
  6. Allergan Inc. $894 16 payments
  7. Sumitomo Pharma America, Inc. $767 30 payments
  8. Lumenis, Inc $639 1 payment
  9. PROCEPT BioRobotics Corporation $584 7 payments
  10. Urovant Sciences Inc $538 19 payments
  11. Other $1,281 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,264 193 payments
  2. Travel and Lodging $2,915 11 payments
  3. Consulting Fee $2,738 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $639 1 payment
Products named General payments · program years 2019–2025
  1. Bulkamid $2,961 20 payments
  2. Axonics $2,832 14 payments
  3. Capio RP $2,064 3 payments
  4. GEMTESA $1,305 49 payments
  5. INTERSTIM $986 13 payments
  6. BOTOX Urology $861 15 payments
  7. Altis $565 8 payments
  8. BOTOX Urology $467 4 payments
  9. BOTOX Botox Therapeutic $465 8 payments
  10. MYRBETRIQ $396 21 payments
  11. Other $2,571 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,488

Median for Urology: 1,053

Drug cost

$497,370

Median for Urology: $101,464

Branded share of claims

55.6%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gemtesa Vibegron Brand 450 $308,794
Myrbetriq Mirabegron Brand 149 $101,636
Botox Onabotulinumtoxina Brand 52 $42,197
Estradiol Generic 294 $17,828
Mirabegron Er Mirabegron Brand 17 $10,739
Premarin Estrogens, Conjugated Brand 11 $4,841
Trospium Chloride Generic 68 $4,333
Methenamine Hippurate Generic 24 $1,694
Tamsulosin Hcl Generic 103 $1,588
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 12 $991

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$143,367

Of which drugs: $14,287

Medicare patients

278

Average age 75

Services billed

3,581

216 women, 62 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 58%
Diabetes 31%
Ischemic heart disease 29%
Osteoporosis 29%
Depression 25%
Chronic kidney disease 23%
Cancer 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 14 2,100 $9,476

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $399
$399 450 —
BOTOX
  • AbbVie, Inc. $158
$158 52 2,100

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

210 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record